Literature DB >> 29084758

The story of Canada's Ebola vaccine.

Francis A Plummer1, Steven M Jones2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29084758      PMCID: PMC5662448          DOI: 10.1503/cmaj.170704

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  9 in total

1.  Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.

Authors:  May S ElSherif; Catherine Brown; Donna MacKinnon-Cameron; Li Li; Trina Racine; Judie Alimonti; Thomas L Rudge; Carol Sabourin; Peter Silvera; Jay W Hooper; Steven A Kwilas; Nicole Kilgore; Christopher Badorrek; W Jay Ramsey; D Gray Heppner; Tracy Kemp; Thomas P Monath; Teresa Nowak; Shelly A McNeil; Joanne M Langley; Scott A Halperin
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

2.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Authors:  Jason A Regules; John H Beigel; Kristopher M Paolino; Jocelyn Voell; Amy R Castellano; Zonghui Hu; Paula Muñoz; James E Moon; Richard C Ruck; Jason W Bennett; Patrick S Twomey; Ramiro L Gutiérrez; Shon A Remich; Holly R Hack; Meagan L Wisniewski; Matthew D Josleyn; Steven A Kwilas; Nicole Van Deusen; Olivier Tshiani Mbaya; Yan Zhou; Daphne A Stanley; Wang Jing; Kirsten S Smith; Meng Shi; Julie E Ledgerwood; Barney S Graham; Nancy J Sullivan; Linda L Jagodzinski; Sheila A Peel; Judie B Alimonti; Jay W Hooper; Peter M Silvera; Brian K Martin; Thomas P Monath; W Jay Ramsey; Charles J Link; H Clifford Lane; Nelson L Michael; Richard T Davey; Stephen J Thomas
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

3.  Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire.

Authors:  K M Johnson; J V Lange; P A Webb; F A Murphy
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

4.  Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent.

Authors:  E T Bowen; G Lloyd; W J Harris; G S Platt; A Baskerville; E E Vella
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

5.  Attenuated vesicular stomatitis viruses as vaccine vectors.

Authors:  A Roberts; L Buonocore; R Price; J Forman; J K Rose
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Authors:  Steven M Jones; Heinz Feldmann; Ute Ströher; Joan B Geisbert; Lisa Fernando; Allen Grolla; Hans-Dieter Klenk; Nancy J Sullivan; Viktor E Volchkov; Elizabeth A Fritz; Kathleen M Daddario; Lisa E Hensley; Peter B Jahrling; Thomas W Geisbert
Journal:  Nat Med       Date:  2005-06-05       Impact factor: 53.440

7.  A system for functional analysis of Ebola virus glycoprotein.

Authors:  A Takada; C Robison; H Goto; A Sanchez; K G Murti; M A Whitt; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

8.  Effective post-exposure treatment of Ebola infection.

Authors:  Heinz Feldmann; Steven M Jones; Kathleen M Daddario-DiCaprio; Joan B Geisbert; Ute Ströher; Allen Grolla; Mike Bray; Elizabeth A Fritz; Lisa Fernando; Friederike Feldmann; Lisa E Hensley; Thomas W Geisbert
Journal:  PLoS Pathog       Date:  2007-01       Impact factor: 6.823

9.  Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).

Authors:  Ana Maria Henao-Restrepo; Anton Camacho; Ira M Longini; Conall H Watson; W John Edmunds; Matthias Egger; Miles W Carroll; Natalie E Dean; Ibrahima Diatta; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Pierre-Stéphane Gsell; Stefanie Hossmann; Sara Viksmoen Watle; Mandy Kader Kondé; Sakoba Kéïta; Souleymane Kone; Eewa Kuisma; Myron M Levine; Sema Mandal; Thomas Mauget; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; John-Arne Røttingen; Marie-Paule Kieny
Journal:  Lancet       Date:  2016-12-23       Impact factor: 79.321

  9 in total
  3 in total

Review 1.  Biodefence research two decades on: worth the investment?

Authors:  Carrie M Long; Andrea Marzi
Journal:  Lancet Infect Dis       Date:  2021-08       Impact factor: 71.421

Review 2.  Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.

Authors:  Anahita Fathi; Christine Dahlke; Marylyn M Addo
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

Review 3.  Natural killer cell responses to emerging viruses of zoonotic origin.

Authors:  Carlos Diaz-Salazar; Joseph C Sun
Journal:  Curr Opin Virol       Date:  2020-08-09       Impact factor: 7.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.